Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DupuytrEn Treatment EffeCtiveness Trial (DETECT)
2024-515110-40-00Phase 3Authorised
- Sponsor
- Pirkanmaan hyvinvointialue
- Start
- Sep 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of collagenase clostridium histolyticum in Dupuytren's contracture (3 arms), sponsored by Pirkanmaan hyvinvointialue. Primary endpoint: Success at five years. Planned start Sep 2024; status: authorised.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Dupuytren's contracture
Beyond the preview
Go deeper on 2024-515110-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515110-40-00.